메뉴 건너뛰기




Volumn 67, Issue 10, 2013, Pages 1050-1056

Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. The full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL;

EID: 84884914733     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12188     Document Type: Article
Times cited : (17)

References (17)
  • 1
    • 0024391923 scopus 로고
    • Neuropsychological assessment of the severely impaired elderly patient
    • Saxton J, Swihart AA,. Neuropsychological assessment of the severely impaired elderly patient. Clin Geriatr Med 1989; 5: 531-43.
    • (1989) Clin Geriatr Med , vol.5 , pp. 531-543
    • Saxton, J.1    Swihart, A.A.2
  • 2
    • 0030801505 scopus 로고    scopus 로고
    • The severe impairment battery: Concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study
    • Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 (Suppl. 2): S51-6.
    • (1997) Alzheimer Dis Assoc Disord , vol.11 , Issue.SUPPL. 2
    • Schmitt, F.A.1    Ashford, W.2    Ernesto, C.3
  • 3
    • 34548081204 scopus 로고    scopus 로고
    • Donepezil preserves cognition and global function in patients with severe Alzheimer disease
    • Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69: 459-69.
    • (2007) Neurology , vol.69 , pp. 459-469
    • Black, S.E.1    Doody, R.2    Li, H.3
  • 4
    • 47849098036 scopus 로고    scopus 로고
    • Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease
    • Emre M, Mecocci P, Stender K,. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease. J Alzheimers Dis 2008; 14: 193-9.
    • (2008) J Alzheimers Dis , vol.14 , pp. 193-199
    • Emre, M.1    Mecocci, P.2    Stender, K.3
  • 5
    • 43049134839 scopus 로고    scopus 로고
    • Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, randomized trial
    • Homma A, Imai Y, Tago H, et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 2008; 25: 399-407.
    • (2008) Dement Geriatr Cogn Disord , vol.25 , pp. 399-407
    • Homma, A.1    Imai, Y.2    Tago, H.3
  • 6
    • 33748567769 scopus 로고    scopus 로고
    • A systematic review of assessment and treatment of moderate to severe Alzheimer's disease
    • Schmitt FA, Wichems CH,. A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. Prim Care Companion J Clin Psychiatry 2006; 8: 158-9.
    • (2006) Prim Care Companion J Clin Psychiatry , vol.8 , pp. 158-159
    • Schmitt, F.A.1    Wichems, C.H.2
  • 7
    • 33645741379 scopus 로고    scopus 로고
    • Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study
    • Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057-65.
    • (2006) Lancet , vol.367 , pp. 1057-1065
    • Winblad, B.1    Kilander, L.2    Eriksson, S.3
  • 8
    • 69949154414 scopus 로고    scopus 로고
    • Treatment effects of memantine on language in moderate to severe Alzheimer's disease patients
    • Ferris S, Ihl R, Robert P, et al. Treatment effects of memantine on language in moderate to severe Alzheimer's disease patients. Alzheimers Dement 2009; 5: 369-74.
    • (2009) Alzheimers Dement , vol.5 , pp. 369-374
    • Ferris, S.1    Ihl, R.2    Robert, P.3
  • 9
    • 23844474755 scopus 로고    scopus 로고
    • Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease
    • Galasko D, Schmitt F, Thomas R, Jin S, Bennett D,. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc 2005; 11: 446-53.
    • (2005) J Int Neuropsychol Soc , vol.11 , pp. 446-453
    • Galasko, D.1    Schmitt, F.2    Thomas, R.3    Jin, S.4    Bennett, D.5
  • 10
    • 75949130369 scopus 로고    scopus 로고
    • A brief instrument to assess treatment response in the patient with advanced Alzheimer disease
    • Schmitt FA, Saxton JA, Xu Y, et al. A brief instrument to assess treatment response in the patient with advanced Alzheimer disease. Alzheimer Dis Assoc Disord 2009; 23: 377-83.
    • (2009) Alzheimer Dis Assoc Disord , vol.23 , pp. 377-383
    • Schmitt, F.A.1    Saxton, J.A.2    Xu, Y.3
  • 11
    • 77955253242 scopus 로고    scopus 로고
    • Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study
    • Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010; 32: 1234-51.
    • (2010) Clin Ther , vol.32 , pp. 1234-1251
    • Farlow, M.R.1    Salloway, S.2    Tariot, P.N.3
  • 13
    • 80052025326 scopus 로고    scopus 로고
    • Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
    • Ferris SH, Schmitt FA, Saxton J, et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimers Res Ther 2011; 3: 22.
    • (2011) Alzheimers Res Ther , vol.3 , pp. 22
    • Ferris, S.H.1    Schmitt, F.A.2    Saxton, J.3
  • 14
    • 0030819805 scopus 로고    scopus 로고
    • A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: Overview and general results. The Alzheimer's Disease Cooperative Study
    • Ferris SH, Mackell JA, Mohs R, et al. A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 (Suppl. 2): S1-12.
    • (1997) Alzheimer Dis Assoc Disord , vol.11 , Issue.SUPPL. 2
    • Ferris, S.H.1    MacKell, J.A.2    Mohs, R.3
  • 15
    • 0028152357 scopus 로고
    • Severe impairment battery. A neuropsychological test for severely demented patients
    • Panisset M, Roudier M, Saxton J, Boller F,. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol 1994; 51: 41-5.
    • (1994) Arch Neurol , vol.51 , pp. 41-45
    • Panisset, M.1    Roudier, M.2    Saxton, J.3    Boller, F.4
  • 16
    • 16844383073 scopus 로고    scopus 로고
    • Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: A 12-month analysis
    • Feldman HH, Van BB, Kavanagh SM, Torfs KE,. Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Dis Assoc Disord 2005; 19: 29-36.
    • (2005) Alzheimer Dis Assoc Disord , vol.19 , pp. 29-36
    • Feldman, H.H.1    Van, B.B.2    Kavanagh, S.M.3    Torfs, K.E.4
  • 17
    • 0036176148 scopus 로고    scopus 로고
    • Factorial validation of the Severe Impairment Battery for patients with Alzheimer's disease. A pilot study
    • Pelissier C, Roudier M, Boller F,. Factorial validation of the Severe Impairment Battery for patients with Alzheimer's disease. A pilot study. Dement Geriatr Cogn Disord 2002; 13: 95-100.
    • (2002) Dement Geriatr Cogn Disord , vol.13 , pp. 95-100
    • Pelissier, C.1    Roudier, M.2    Boller, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.